

Adriana E Rosato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/533888/publications.pdf>

Version: 2024-02-01

40
papers

1,449
citations

331670

21
h-index

330143

37
g-index

41
all docs

41
docs citations

41
times ranked

1933
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid detection of the widely circulating B.1.617.2 (Delta) SARS-CoV-2 variant. <i>Pathology</i> , 2022, 54, 351-356.	0.6	13
2	Impact of PrsA on membrane lipid composition during daptomycin-resistance-mediated β -lactam sensitization in clinical MRSA strains. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 135-147.	3.0	5
3	Impact of Bicarbonate on PBP2a Production, Maturation, and Functionality in Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	9
4	<i>Staphylococcus pseudintermedius</i> ™s PBP4 Is Directly Associated with the Dissociated Oxacillin and Cefoxitin Phenotype. <i>Antibiotics</i> , 2021, 10, 1299.	3.7	4
5	Efficacy of newly generated short antimicrobial cationic lipopeptides against methicillin-resistant <i>Staphylococcus aureus</i> (MRSA). <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105827.	2.5	13
6	Tedizolid is a promising antimicrobial option for the treatment of <i>Staphylococcus aureus</i> infections in cystic fibrosis patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 126-134.	3.0	13
7	Carbapenems drive the collateral resistance to ceftaroline in cystic fibrosis patients with MRSA. <i>Communications Biology</i> , 2020, 3, 599.	4.4	9
8	Characterization of the First <i>mecA</i> -Positive Multidrug-Resistant <i>Staphylococcus pseudintermedius</i> Isolated from an Argentinian Patient. <i>Microbial Drug Resistance</i> , 2020, 26, 717-721.	2.0	9
9	Identification and molecular epidemiology of methicillin resistant <i>Staphylococcus pseudintermedius</i> strains isolated from canine clinical samples in Argentina. <i>BMC Veterinary Research</i> , 2019, 15, 264.	1.9	25
10	VraSR and Virulence Trait Modulation during Daptomycin Resistance in Methicillin-Resistant <i>Staphylococcus aureus</i> Infection. <i>MSphere</i> , 2019, 4, .	2.9	32
11	Combination Antibiotic Exposure Selectively Alters the Development of Vancomycin Intermediate Resistance in <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	16
12	Activity of Telavancin against <i>Staphylococcus aureus</i> Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	6
13	Molecular Bases Determining Daptomycin Resistance-Mediated Resensitization to β -Lactams (Seesaw) Tj ETQq1 1 0.784314 rgBT /Ov 61, .	3.2	54
14	Daptomycin Resistance in Clinical MRSA Strains Is Associated with a High Biological Fitness Cost. <i>Frontiers in Microbiology</i> , 2017, 8, 2303.	3.5	51
15	Telavancin Displays Activity Against Cystic Fibrosis-Associated MRSA Strains Including Those With Increased Resistance to Ceftaroline. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
16	Modeling Meropenem Treatment, Alone and in Combination with Daptomycin, for KPC-Producing <i>Klebsiella pneumoniae</i> Strains with Unusually Low Carbapenem MICs. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5047-5050.	3.2	9
17	The <i>Staphylococcus aureus</i> Chaperone PrsA Is a New Auxiliary Factor of Oxacillin Resistance Affecting Penicillin-Binding Protein 2A. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1656-1666.	3.2	60
18	Impact of efflux in the development of multidrug resistance phenotypes in <i>Staphylococcus aureus</i> . <i>BMC Microbiology</i> , 2015, 15, 232.	3.3	34

#	ARTICLE	IF	CITATIONS
19	Staphylococcal Phenotypes Induced by Naturally Occurring and Synthetic Membrane-Interactive Polyphenolic β -Lactam Resistance Modifiers. <i>PLoS ONE</i> , 2014, 9, e93830.	2.5	23
20	TCA Cycle-Mediated Generation of ROS Is a Key Mediator for HeR-MRSA Survival under β -Lactam Antibiotic Exposure. <i>PLoS ONE</i> , 2014, 9, e99605.	2.5	43
21	Identification of Point Mutations in Clinical <i>Staphylococcus aureus</i> Strains That Produce Small-Colony Variants Auxotrophic for Menadione. <i>Infection and Immunity</i> , 2014, 82, 1600-1605.	2.2	57
22	PBP2a Mutations Causing High-Level Ceftaroline Resistance in Clinical Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6668-6674.	3.2	120
23	Ceftaroline Is Active against Heteroresistant Methicillin-Resistant <i>Staphylococcus aureus</i> Clinical Strains despite Associated Mutational Mechanisms and Intermediate Levels of Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5736-5746.	3.2	23
24	Targeting of PBP1 by β -lactams Determines recA/SOS Response Activation in Heterogeneous MRSA Clinical Strains. <i>PLoS ONE</i> , 2013, 8, e61083.	2.5	25
25	Exposure of Clinical MRSA Heterogeneous Strains to β -Lactams Redirects Metabolism to Optimize Energy Production through the TCA Cycle. <i>PLoS ONE</i> , 2013, 8, e71025.	2.5	17
26	VraSR Two-Component Regulatory System Contributes to <i>mprF</i> -Mediated Decreased Susceptibility to Daptomycin in <i>In Vivo</i> -Selected Clinical Strains of Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 92-102.	3.2	122
27	β -Lactams Increase the Antibacterial Activity of Daptomycin against Clinical Methicillin-Resistant <i>Staphylococcus aureus</i> Strains and Prevent Selection of Daptomycin-Resistant Derivatives. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6192-6200.	3.2	121
28	Thiadiazolidinones: A new class of alanine racemase inhibitors with antimicrobial activity against methicillin-resistant <i>Staphylococcus aureus</i> . <i>Biochemical Pharmacology</i> , 2012, 83, 368-377.	4.4	18
29	Fate of Mutation Rate Depends on <i>agr</i> Locus Expression during Oxacillin-Mediated Heterogeneous-Homogeneous Selection in Methicillin-Resistant <i>Staphylococcus aureus</i> Clinical Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3176-3186.	3.2	16
30	Trial of Universal Gloving with Emollient-Impregnated Gloves to Promote Skin Health and Prevent the Transmission of Multidrug-Resistant Organisms in a Surgical Intensive Care Unit. <i>Infection Control and Hospital Epidemiology</i> , 2010, 31, 491-497.	1.8	46
31	Nasal carriage of inducible dormant and community-associated methicillin-resistant <i>Staphylococcus aureus</i> in an ambulatory population of predominantly university students. <i>International Journal of Infectious Diseases</i> , 2010, 14, e18-e24.	3.3	12
32	Differential Expression of <i>ccrA</i> in Methicillin-Resistant <i>Staphylococcus aureus</i> Strains Carrying Staphylococcal Cassette Chromosome Type II and IVa Elements. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4556-4558.	3.2	21
33	Development of homogeneous expression of resistance in methicillin-resistant <i>Staphylococcus aureus</i> clinical strains is functionally associated with a β -lactam-mediated SOS response. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 37-45.	3.0	50
34	Unusual form of oxacillin resistance in methicillin-resistant <i>Staphylococcus aureus</i> clinical strains. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 61, 387-395.	1.8	33
35	Identification and Phenotypic Characterization of a β -Lactam-Dependent, Methicillin-Resistant <i>Staphylococcus aureus</i> Strain. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2514-2522.	3.2	18
36	Susceptibility of coagulase-negative staphylococcal nosocomial bloodstream isolates to the chlorhexidine/silver sulfadiazine-impregnated central venous catheter. <i>American Journal of Infection Control</i> , 2004, 32, 486-488.	2.3	9

#	ARTICLE	IF	CITATIONS
37	<i>mecA</i> - blaZ Corepressors in Clinical <i>Staphylococcus aureus</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1460-1463.	3.2	56
38	Quantitation of <i>mecA</i> Transcription in Oxacillin-Resistant <i>Staphylococcus aureus</i> Clinical Isolates. <i>Journal of Bacteriology</i> , 2003, 185, 3446-3452.	2.2	30
39	Related Clones Containing SCCmec Type IV Predominate among Clinically Significant <i>Staphylococcus epidermidis</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3574-3579.	3.2	178
40	Inducible Macrolide Resistance in <i>Corynebacterium jeikeium</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1982-1989.	3.2	49